

## Daily evidence digest

5 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### The COVID Positive Pathway in Melbourne, non-pharmacological interventions, preparing for the next COVID-19 viral variant

#### Peer reviewed journals featured:

- Observational studies on:
  - The COVID Positive Pathway involving public health agencies, primary care, and hospitals in Melbourne [here](#)
  - Association between metformin use and mortality in patients with COVID-19 and type 2 diabetes mellitus [here](#)
  - A dataset of non-pharmaceutical interventions against SARS-CoV-2 in Europe [here](#)
  - Viral loads in deceased COVID-19 vaccinees [here](#)
  - The relationship between inflammation biomarkers and liver damage in COVID-19 inpatients [here](#)
- A modelling study on COVID-19 mortality as US states relax nonpharmacologic interventions [here](#)
- A consensus statement on long COVID (post-COVID-19 condition) in children [here](#)
- An editorial on preparing for the next COVID-19 viral variant [here](#)
- Commentary on research in the US on COVID-19's long-term effects [here](#)

#### Letters and correspondence discussed:

- A Virtual Inpatient Diabetes Management Service developed in the wake of COVID-19 in NSW [here](#)
- SARS-CoV-2 infection rates and outcomes with Omicron and Delta in US children under 5 [here](#)
- Association between SARS-CoV-2 viral load in wastewater and reported cases, hospitalisations, and vaccinations in Milan [here](#)

#### Pre-peer review articles featured:

- Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation [here](#)
- Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads [here](#)
- A “MixOmicron” hybrid undetected by qPCRs that screen for variants in routine diagnosis [here](#)
- Safety and immunogenicity of a reduced dose of Comirnaty (Pfizer) vaccine (REDU-VAC) [here](#)
- A systematic review on myocarditis following COVID-19 vaccination [here](#)
- A randomised controlled trial of remdesivir for treating hospitalised COVID-19 patients [here](#)
- Effect of vaccination rates on the prevalence and mortality of COVID-19 [here](#)

- Long-term psychological consequences of long COVID (post-acute COVID-19 syndrome) [here](#)
- Immunogenicity of Comirnaty (Pfizer) primary vaccination in recovered healthcare workers [here](#)
- Mass distribution of rapid antigen tests and SARS-CoV-2 prevalence in Michigan [here](#)
- A phase 3 randomised controlled study of camostat mesilate (FOY-305) for treating COVID-19 [here](#)
- Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population [here](#)

## Guidance and reports

- The World Health Organization published an update of its COVID-19 vaccine tracker [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)

## News and blogs

- New initiatives to advance mRNA vaccine production in Africa [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).